Cancer Epidemiology Biomarkers & Prevention 17, 736, March 1, 2008. doi: 10.1158/1055-9965.EPI-07-2832
© 2008 American Association for Cancer Research
No Association between hOGG1, XRCC1, and XPD Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, or Esophageal Adenocarcinoma: Results from the Factors Influencing the Barrett's Adenocarcinoma Relationship Case-Control Study
Heather R. Ferguson1,
Christopher P. Wild5,
Lesley A. Anderson2,
Seamus J. Murphy6,
Brian T. Johnston3,
Liam J. Murray2,
R.G. Peter Watson3,
Jim McGuigan4,
John V. Reynolds7 and
Laura J. Hardie5
1 Division of Gastroenterology, Belfast City Hospital; 2 Centre for Clinical and Population Sciences, Queen's University; Divisions of 3 Gastroenterology and 4 Surgery, Royal Group of Hospitals, Belfast, United Kingdom; 5 Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United Kingdom; 6 Division of Gastroenterology, Daisy Hill Hospital, Newry, United Kingdom; and 7 Division of Surgery, St. James's Hospital, Dublin, Ireland
Requests for reprints: Heather R. Ferguson, Level 6 North, Belfast City Hospital, Belfast BT9 7AB, Northern Ireland. Phone: 44-2890-632602; Fax: 44-2890-231907. E-mail: hrferguson{at}doctors.net.uk
 |
Abstract
|
|---|
Reflux of gastric contents can lead to development of reflux esophagitis and Barrett's esophagus. Barrett's esophagus is a risk factor for esophageal adenocarcinoma. Damage to DNA may lead to carcinogenesis but is repaired through activation of pathways involving polymorphic enzymes, including human 8-oxoguanine glycosylase 1 (hOGG1), X-ray repair cross-complementing 1 (XRCC1), and xeroderma pigmentosum group D (XPD). Of the single nucleotide polymorphisms identified in these genes, hOGG1 Ser326Cys, XRCC1 Arg399Gln, and XPD Lys751Gln are particularly common in Caucasians and have been associated with lower DNA repair capacity. Small studies have reported associations with XPD Lys751Gln and esophageal adenocarcinoma. XRCC1 Arg399Gln has been linked to Barrett's esophagus and reflux esophagitis. In a population-based case-control study, we examined associations of the hOGG1 Ser326Cys, XRCC1 Arg399Gln, and XPD Lys751Gln polymorphisms with risk of esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis. Genomic DNA was extracted from blood samples collected from cases of esophageal adenocarcinoma (n = 210), Barrett's esophagus (n = 212), reflux esophagitis (n = 230), and normal population controls frequency matched for age and sex (n = 248). Polymorphisms were genotyped using TaqMan allelic discrimination assays. Odds ratios and 95% confidence intervals were obtained from logistic regression models adjusted for potential confounding factors. There were no statistically significant associations between these polymorphisms and risk of esophageal adenocarcinoma, Barrett's esophagus, or reflux esophagitis. (Cancer Epidemiol Biomarkers Prev 2008;17(3):736–9)
|
Introduction
|
|---|
Reflux of gastric contents can lead to development of reflux esophagitis and Barrett's esophagus. Barrett's esophagus is an important risk factor for esophageal adenocarcinoma, the incidence of which has increased in recent years (1, 2). Damage to DNA may lead to carcinogenesis (3) but is repaired through activation of pathways involving polymorphic enzymes (4). Human 8-oxoguanine glycosylase 1 (hOGG1) and X-ray repair cross-complementing 1 (XRCC1) act on the base excision repair pathway. Xeroderma pigmentosum group D (XPD) enzyme is involved in the nucleotide excision repair pathway (5). Various single nucleotide polymorphisms have been identified in these genes, but hOGG1 Ser326Cys, XRCC1 Arg399Gln, and XPD Lys751Gln are particularly common in Caucasians and have been associated with lower DNA repair capacity (6-8). Small studies have reported associations with XPD Lys751Gln and esophageal adenocarcinoma (9-11). XRCC1 Arg399Gln has been linked to Barrett's esophagus and reflux esophagitis (11). We investigated associations between hOGG1 Ser326Cys, XRCC1 Arg399Gln, and XPD Lys751Gln and risk of esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis in a large case-control study.
|
Materials and Methods
|
|---|
Design
The study methods have been described previously in detail (12). In summary, the Factors Influencing the Barrett's Adenocarcinoma Relationship study was carried out in Ireland between March 2002 and July 2005. Data and samples were collected from Caucasians with (a) esophageal adenocarcinoma, (b) Barrett's esophagus, (c) reflux esophagitis, and (d) normal controls.
Genotyping
The Puregene DNA purification kit (Gentra Systems) was used to extract DNA from blood samples. The hOGG1 Ser326Cys (rs1052133), XRCC1 Arg399Gln (rs25487), and XPD Lys751Gln (rs13181) polymorphisms were genotyped using TaqMan allelic discrimination assays (Applied Biosystems). As a quality-control measure, genotyping was repeated for 10% of the samples, and the replicates were 100% concordant.
Statistical Analysis
Departures from Hardy-Weinberg equilibrium were tested for using the goodness-of-fit 
2 test. Genotype frequencies among cases of esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis were compared with controls using the 2 test for association while adjusting for potential confounding factors by logistic regression. Statistical significance was set at P < 0.05. Analyses were done using SPSS for Windows version 13.0 (SPSS).
|
Results
|
|---|
The Factors Influencing the Barrett's Adenocarcinoma Relationship study recruited a total of 227 esophageal adenocarcinoma patients, 224 Barrett's esophagus patients, 230 reflux esophagitis patients, and 260 population controls. The demographic characteristics of each group are presented in Table 1
. The participation rates of Barrett's esophagus and reflux esophagitis patients and control subjects were 82.4%, 68.7%, and 41.8%, respectively. The participation rate of eligible, alive esophageal adenocarcinoma patients was 74.2% and the overall esophageal adenocarcinoma response rate was 63.9%. DNA samples were available for analysis from 210 (92.5%) esophageal adenocarcinoma patients, 212 (94.6%) Barrett's esophagus patients, 230 (100%) reflux esophagitis patients, and 248 (95.4%) controls.
View this table:
[in this window]
[in a new window]
|
Table 1. Characteristics of controls, reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma patients
|
|
The distribution and frequency of genotypes for cases and controls are shown in Table 2
. There were no significant departures from Hardy-Weinberg equilibrium for any of the polymorphisms in any of the subject groups. For controls, the frequency of polymorphic variants was 0.24 (hOGG1 Ser326Cys), 0.36 (XRCC1 Arg399Gln), and 0.38 (XPD Lys751Gln). These were similar to frequencies reported in Caucasians in the SNP500 Database (http://snp500cancer.nci.nih.gov).
View this table:
[in this window]
[in a new window]
|
Table 2. Frequency of hOGG1, XRCC1, and XPD genotypes and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma, relative to asymptomatic controls
|
|
There were no statistically significant associations between the hOGG1 Ser326Cys, XRCC1 Arg399Gln, and XPD Lys751Gln polymorphisms and the risk of esophageal adenocarcinoma, Barrett's esophagus, or reflux esophagitis.
|
Discussion
|
|---|
To date, this is the largest case-control study to explore the association between DNA repair gene polymorphisms and risk of esophageal adenocarcinoma. In addition, it is the first population-based study to evaluate the role of these polymorphisms in Barrett's esophagus and reflux esophagitis. All three polymorphisms were in Hardy-Weinberg equilibrium and had sufficient statistical power (>80%) to detect an odds ratio (OR) of >2.0. Further strengths of our study include the population-based design and clear characterization of phenotypes to minimize misclassification bias. Detailed interview data allowed us to control for a range of potential confounding factors, and DNA was available for analysis in almost all subjects.
Our findings are in contrast to results from a Swedish case-control study, which suggested that the XPD Lys751Gln polymorphism was associated with a significantly increased risk of esophageal adenocarcinoma (10). This study also had a population-based design, strict definition of phenotypes, and detailed interview data. However, DNA was available for analysis in only 50% of interviewed subjects, questioning the internal validity of the study. In addition, the present study included over two times the number of esophageal adenocarcinoma subjects. Liu et al. also reported an increased risk of esophageal adenocarcinoma in association with the XPD Lys751Gln polymorphism (9). Although this study was a reasonable size, with 183 esophageal adenocarcinoma subjects recruited, major limitations were its hospital-based design and lack of complete case ascertainment. In a Canadian study, Casson et al. reported further conflicting results, suggesting that the XPD Lys751Gln polymorphism was associated with a reduced risk of esophageal adenocarcinoma (11). This study was limited by its hospital-based design and small sample size, including only 56 esophageal adenocarcinoma subjects.
In keeping with our results, all three previous studies have reported no association with the XRCC1 Arg399Gln polymorphism and risk of esophageal adenocarcinoma (9-11). However, in the only previous study to investigate DNA repair polymorphisms in Barrett's esophagus and reflux esophagitis, Casson et al. reported a reduced risk of these conditions in association with XRCC1 Arg399Gln (11). The limitations of this study have been discussed and it is likely that results from our study are more robust given that we recruited over double the number of study subjects.
We reported no association between the hOGG1 Ser326Cys polymorphism and risk of esophageal adenocarcinoma, Barrett's esophagus, or reflux esophagitis. No previous study has investigated this polymorphism in relation to these conditions.
However, association studies in esophageal squamous cell carcinoma have produced conflicting results (13, 14). A limitation of our study was inadequate power to detect a modest excess risk (OR < 2.0) or to examine the role of possible gene-environment interactions.
In summary, we found no significant associations between the hOGG1 Ser326Cys, XRCC1 Arg399Gln, and XPD Lys751Gln polymorphisms and the risk of esophageal adenocarcinoma, Barrett's esophagus, or reflux esophagitis.
|
Footnotes
|
|---|
Grant support: Ireland-Northern Ireland Co-operation Research Project grant sponsored by the Research and Development Office (Belfast, Northern Ireland) and Health Research Board (Dublin, Ireland) and by the Ulster Cancer Foundation (Belfast, Northern Ireland); Northern Ireland Research and Development Office Clinical Fellowship.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 11/27/07;
accepted 12/21/07.
|
References
|
|---|
- Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004;53:1070–4.[Abstract/Free Full Text]
- Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142–6.[Abstract/Free Full Text]
- Weiss JM, Goode EL, Ladiges WC, Ulrich CM. Polymorphic variation in hOGG1 and risk of cancer: a review of the functional and epidemiologic literature. Mol Carcinog 2005;42:127–41.[CrossRef][Medline]
- Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513–30.[Abstract/Free Full Text]
- Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 2005;161:1–14.[Abstract/Free Full Text]
- Hill JW, Evans MK. Dimerization and opposite base-dependent catalytic impairment of polymorphic S326C OGG1 glycosylase. Nucleic Acids Res 2006;34:1620–32.[Abstract/Free Full Text]
- Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59:2557–61.[Abstract/Free Full Text]
- Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354–7.[Abstract/Free Full Text]
- Liu G, Zhou W, Yeap BY, et al. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis 2007;28:1254–8.[Abstract/Free Full Text]
- Ye W, Kumar R, Bacova G, Lagergren J, Hemminki K, Nyren O. The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. Carcinogenesis 2006;27:1835–41.[Abstract/Free Full Text]
- Casson AG, Zheng Z, Evans SC, Veugelers PJ, Porter GA, Guernsey DL. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Carcinogenesis 2005;26:1536–41.[Abstract/Free Full Text]
- Anderson LA, Johnston BT, Watson RG, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 2006;66:4975–82.[Abstract/Free Full Text]
- Xing DY, Tan W, Song N, Lin DX Ser326Cys polymorphism in hOGG1 gene and risk of esophageal cancer in a Chinese population. Int J Cancer 2001;95:140–3.[CrossRef][Medline]
- Hao B, Wang H, Zhou K, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004;64:4378–84.[Abstract/Free Full Text]
Top
Abstract
Introduction
